By vgreene, 13 November, 2020 Consider urine cytology in pts w persistent hematuria and irritative voiding sx or risk factors for carcinoma in situ evidence insufficient for urine based tumor markers1
By vgreene, 13 November, 2020 If pt develops gross hematuria 1 2 uarr degree of hematuria or new urologic sx initiate further eval1
By vgreene, 13 November, 2020 If microhematuria persists recurs engage in shared decision making re further eval pursue additional imaging if renal US used initially1
By vgreene, 13 November, 2020 Consider additional evaluation in pts w persistent or recurrent microhematuria can d c UA monitoring and evaluation in select pts
By vgreene, 13 November, 2020 Don t obtain urine cytology or other urine based molecular markers for bladder CA in initial eval1 3
